|
Diagnosis and Evidence-Based Management of T-Cell Lymphoma
STATEMENT OF NEED
T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis and treatment challenging (Salem et al, 2021). In this webinar, Aaron Goodman, MD, will update clinic... |
|
An Illustrated Guide to Meeting the Challenges of Treating Hemophilia
In this activity, Steven Pipe, MD and Guy Young, MD introduce the unmet medical needs experienced by patients with hemophilia. They review the mechanisms of action and most recent clinical trial data for the most advanced substitution therapies (emicizumab), hemostatic rebalancing agents (concizumab, marstacimab, and fitusiran), and gene therapies. The faculty also discuss how approval of these treatments could affect patient care, and the questions that need to be addressed in ongoing phase 3... |
|
|
New Perspectives in the Management of Marginal Zone Lymphoma
STATEMENT OF NEED
Marginal zone lymphoma (MZL) comprises approximately 7% of all mature non-Hodgkin lymphomas (NHLs) (Cerhan & Haberman, 2021). According to the World Health Organization classification, there are three subtypes: extranodal MZL, also referred to as mucosa-associated lymphatic tissue (MALT) lymphoma; splenic MZL, which originates from memory B lymphocytes located in the marginal zone of secondary lymphoid follicles present in the spleen; and nodal MZL, which originates in... |
|
|
New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease
STATEMENT OF NEED
Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the first year following HSCT but may develop in subsequent years. It most commonly affects the skin; howe... |
|
|
Podcast: New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease
STATEMENT OF NEED
Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the first year following HSCT but may develop in subsequent years. It most commonly affects the skin; howe... |
|
|
Novel Breast Cancer Therapies: Antibody-Drug Conjugates
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, with an estimated 15% of cases being human epidermal growth factor receptor 2 (HER2)"positive and 12% being triple-negative (ACS, 2019). Antibody-drug conjugates have revolutionized the treatment of HER2-positive, triple-negative, and, most recently, HER2-low unresectable or metastatic breast cancer. These drugs combine a tumor antigen"targeted monoclonal antibody with a cytotoxic payload to permit the s... |
|
|
Novel Breast Cancer Therapies: Immune Checkpoint Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is
estimated that 12% of cases are classified as triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) (ACS, 2019). Immune checkpoint inhibition in combination with chemotherapy is a new strategy in breast cancer, with the first immunotherapy approval for patients with advanced triple-negative disease occurring in 2019. Immune checkpoint inhibit... |
|
|
Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Identification of Relapsed ALL
Target Audience
The target audience for this initiative includes hematology/oncology physicians and other members of the multidisciplinary cancer care team involved in the management of patients with acute lymphocytic leukemia.
Program Overview
This activity is the first in a series of four modules on relapsed/refractory acute lymphocytic leukemia (ALL). Module 1 focuses on identification of relapsed ALL. This education is presented by Dr. Reshma Ramlal from the University of Kentucky Mar... |
|
|
Internal Medicine Comprehensive Review and Update 2023 - LIVE STREAMING
Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties
This program, the 63rd Annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care.
This program covers the breadth of Internal Medicine subspecialties, including:
• Cardiovascular Medicine
• Infectious... |
|
|
Paroxysmal Nocturnal Hemoglobinuria (PNH): Real-world Experience
This accredited CME activity, led by Satheesh Chonat, MD, Assistant Professor at Emory University School of Medicine and hematologist-oncologists at the Pediatric Hematology Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, highlights the latest real world data focused on paroxysmal nocturnal hemoglobinuria (PNH). Dr Chonat also provides expert analysis of the data’s clinical relevance for members of the care team to help them manage patients with PNH they may enco... |
|
|
Prostate Cancer: The future of PARP inhibitor combination and the evolving paradigm of treatment strategies
Target Audience
Oncologists, physician assistants, nurse practioners, pharmacists and other healthcare professionals involved in the treatment of prostate cancer.
Program Overview
The overall objective for this program is to improve both the knowledge and competence of healthcare professionals who manage patients with prostate cancer using PARP-inhibitor Combination Treatments.
Learning Objectives
Upon completion of this activity, participants should be better able to:
Discus... |
|
|
Treatment of Relapsed/Refractory Ph+ ALL
Target Audience
The target audience for this initiative includes hematology/oncology physicians and other members of the multidisciplinary cancer care team involved in the management of patients with acute lymphocytic leukemia.
Program Overview
This activity is the second in a series of four educational activities focusing on the treatment of relapsed/refractory ALL. Dr. Jessica Leonard, from Oregon Health and Science University, discusses diagnoses and treatment options, and will wal... |
|
|
Intensive Review of Internal Medicine - IN PERSON or LIVE STREAMING
The Acclaimed Clinical Update and Board Review
With more than 150 lectures, case discussions, and board preparation sessions, this CME program is one of the most comprehensive reviews of internal medicine offered by the clinical faculty of Harvard Medical School.
It offers accelerated learning:
- For clinicians seeking a practical and comprehensive review that ensures you are up to date across all major fields of internal medicine:
• Newer options for diagnosis: what to choose, w... |
|
|
Treatment Paradigms in Advanced Prostate Cancer: Exploring the Role of PARP Inhibitor Combinations
Target Audience
This activity is designed to meet the educational needs of medical oncologists, urologic oncologists, nurse practitioners, PAs, nurses and other healthcare professionals who manage patients with mCRPC.
Program Overview
A focused online module that examines the mechanistic rationale, discusses the latest evidence, and explores the potential role of PARP inhibitor-based combination therapy in the treatment of patients with advanced prostate cancer.
Learning Objectives... |
|
|
Targeting Large B-Cell Lymphoma: Advances in Treatment
TARGET AUDIENCE:
This activity is designed to meet the educational needs of hematology/oncology physicians, nurse practitioners, nurses, PAs, pharmacists, and other healthcare professionals who care for patients with DLBCL.
PROGRAM OVERVIEW:
The archived version of an interactive nationwide webinar focused on advances in the management of patients with diffuse large B-cell lymphoma (DLBCL).
LEARNING OBJECTIVES:
Upon completion of this activity, participants should be better able to:
-... |
|
|
Medical Crossfire®: Strategies to Manage Transfusional Iron Overload in Patients with ß-hemoglobinopathies: Optimizing Patient Outcomes
Target Audience
This educational activity is directed toward hematologists and hematologist-oncologists, as well as pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with β-hemoglobinopathies.
Program Overview
The β-hemoglobinopathies, sickle-cell disease (SCD) and β-thalassemia, are the most common monogenic disorders worldwide. Despite improved medical supportive therapies, there still is significant long-ter... |
|
|
All Abuzz About CLL: Exploring Fixed-Duration Regimens and Cardiotoxicity Management
Target Audience
The intended audience for this activity are hematologic oncologists, hematologists, cardiologists, cardio‐oncologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.
Statement of Need/Program Overview
The emergence of effective therapeutic combinations and the promise of fixed duration treatments holds the potential of improved long-term outcomes and quality of life for patients w... |
|
|
Treatment-Related Adverse Events in Advanced Urothelial Carcinoma
Target Audience
This activity is designed to meet the educational needs of physicians and other healthcare professionals involved in the care of urothelial carcinoma.
Program Overview
This interactive case-based activity requires clinicians to make real-world decisions as they optimize therapeutic strategies for patients with advanced urothelial carcinoma.
Throughout the activity, practitioners will have the opportunity to immediately implement expert guidance and evaluate performance ... |
|
|
What’s My (Next) Line? Treating Relapsed/Refractory Multiple Myeloma When Three Prior Treatment Lines Fail
Although outcomes for patients with multiple myeloma (MM) have improved with targeted agents and combination therapies, most MM patients inevitably relapse. Furthermore, the duration and quality of response to treatment deteriorates following each subsequent line of therapy, and the risk of another relapse rises. The emergence of B-cell maturation antigen (BCMA)-targeting antibody-drug conjugates, bispecific antibodies, CAR T-cell therapy, and novel small-molecule agents has offered innovative... |
|
|
Managing Invasive Candidiasis: Key Strategies to Make a Difference
Target Audience
This activity is directed to physicians with specialties in infectious diseases, pulmonary/critical care medicine, and pathology/laboratory medicine as well as other healthcare providers who care for patients at risk for or diagnosed with invasive candidiasis.
Program Overview
This activity, supported by the CDC, will demonstrate key strategies to optimize management of invasive candidiasis using an infographic-based approach.
Learning Objectives
Upon completion of thi... |
|
|
Update in Hospital Medicine 2023 - LIVE STREAMING
Update in Hospital Medicine will be held online this year, using live streaming, electronic Q&A, and other remote learning technologies.
This 4-day intensive Harvard Medical School CME program updates busy practitioners on current, best practices in hospital medicine. Among the highest-rated HMS CME courses, it covers over 30 core topics, with an emphasis on practical management of common problems:
• • Heart failure
• Atrial fibrillation
• Pregnancy
• Acute coronary syndro... |
|
|
Survival Skills for Today's Gynecologist Fall 2023
This practical course stresses how to enhance your day-to-day office GYN practice with relevant, important procedures and therapies that are easy to master, comfortable to incorporate and solidly reimbursable. Upgrade your skills and clinical approach to meet the needs of your gynecologic patients for the future. Feel good about offering comprehensive, up-to-date information and services that will expand your gynecologic practice while making it more enjoyable and rewarding for you. Whether so... |
|
|
Applying the Latest Clinical Data in Multiple Myeloma Patient Care in the Community Setting
In recent years, there have been significant advances in multiple myeloma (MM) management, including approvals of new drugs and treatment combinations. For some patients, however, the benefits of these advances remain elusive: disparities in MM care among Black patients, who are more likely to be treated in the community setting, persist across the spectrum of MM care.
Though evidence-based MM treatment guidelines and consensus statements are available, ongoing studies continue to provide i... |
|
|
Improving Outcomes for Adolescent/Young Adult and Adult Patients with ALL: Evaluating the Impact of Immunotherapy
Target Audience
The activity is intended primarily for hematology/oncology and medical oncology physicians and advanced practitioners caring for adult and AYA patients. Pediatric hematology/oncology and oncology clinicians who care for AYA patients may also find this material useful.
Program Overview
On-demand Oncology Expert Exchange: Clinical Case Challenge activity (Virtual Video Roundtable with Clinical Cases) with compelling reinforcing features. This initiative aims to close knowled... |
|
|
Integrating the Latest Evidence on Immune Checkpoint Inhibitors Into the Management of Advanced Non-Small Cell Lung Cancer
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Rural counties in the US face a higher incidence of lung cancer than urban areas and also have higher rates of cancer-related mortality and other negative treatment outcomes. These statistics underscore the need for increased education among oncology clinicians in order to i... |
|
|
Clinical ShowCase™ in aHUS: The Application of Complement Inhibitors in Practice
Target Audience
This educational activity is directed toward hematologists, nephrologists, primary care physicians, physician assistants, nurse practitioners, and nurses specializing in hematology and transplant medicine who may encounter patients with atypical hemolytic uremic syndrome (aHUS).
Program Overview
This online activity is designed to provide concise and easy-to-digest education in an engaging and interactive case-based format. The case focuses on diagnosing aHUS and choosing ... |
|
|
Transfusion-Related Iron Overload"Evidence-Based Approaches to Improve Chelation Outcomes
Target Audience
This educational activity is directed toward hematologists. Pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with iron overload are also invited to attend.
Program Overview
Patients who require ongoing red blood cell transfusions, such as individuals with transfusion-dependent thalassemia or sickle cell disease, may develop iron overload. Severe or long-term iron overload can result in a higher ri... |
|
|
Nursing Management of Cancer Treatment-Induced Cardiotoxicity
Studies have shown that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. This activity reviews recent advances in the management of cancer teatment-induced cardiotoxicity.
STATEMENT OF NEED
Several studies reveal that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. Adverse cardiac effects may occur immediately after cessation of therapy or, in som... |
|
|
Putting the CAR(T) Before the Horse: Practicalities of T Cell-Activating Therapies in Multiple Myeloma
ACTIVITY DESCRIPTION
Patients with multiple myeloma that is refractory to multiple classes of therapeutics can be particularly difficult to treat. Fortunately, the treatment landscape is expanding, and a range of new therapies for patients with multiply relapsed or refractory multiple myeloma (RRMM) is rapidly emerging. In particular, chimeric antigen receptor (CAR) T-cell therapy is a powerful new immunotherapy that has revolutionized cancer treatment and has been approved for patients with ... |
|
|
Community Practice Connections™: Visualizing New Treatment Pathways for Anemia in Chronic Kidney Disease
Target Audience
This educational activity is directed toward hematologists, nurses, and other health care professionals involved in the treatment of patients with CKD-related anemia.
Program Overview
Anemia is a common complication in chronic kidney disease (CKD) and is associated with a reduced quality of life, an increase in morbidity and mortality and higher costs. Anemia is associated with major complications for patients with CKD, including impaired cognition, sleep disturbance, and ... |
|
|
Community Practice Connections™: Transforming How We Treat Sickle Cell Disease: Holistic Approaches to Addressing Clinical Challenges Across the Patient’s Lifespan
Target Audience
This activity is directed toward hematologists, pediatricians, emergency medicine clinicians, pain management specialists, specialty NPs, PAs, RNs, and other HCPs involved in the management of patients with SCD.
Program Overview
Significant progress has been made in the management of sickle cell disease (SCD) in recent years, leading to increased life expectancy for patients. The number of available medications continues to grow; further, novel agents and gene therapies on... |
|
|
Community Practice Connections™: Exploring the Potential Role for Gene Therapy in Hemophilia B
Target Audience
This activity is directed toward hematologists and hematologist-oncologists. Pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with hemophilia B are invited to participate.
Activity Overview
In hemophilia B, an absence of clotting factor IX leads to a failure to facilitate and stabilize the primary platelet and fibrin plug that initially forms a clot. As a result, patients experience prolonged blee... |
|
|
A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL/SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion f... |
|
|
Ace the Case: Multiple Myeloma Presentation in the Community Setting
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, h... |
|
|
Ace the Case: Treating First Multiple Myeloma Relapse in the Community Setting
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, h... |
|
|
Ace the Case: R/R MM After 4 Lines of Therapy: What are the options?
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, h... |
|
|
Ace the Case: Newly Diagnosed AML: Can Molecular Markers Direct Treatment?
Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications. |
|
|
Ace the Case: Older Adult with Therapy-Related AML
Knowledge of the key management issues for patients with AML is critical Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications. |
|
|
Ace the Case: Supporting Older Adults with AML
Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications. |
|
|
Expert Illustrations & Commentaries™: Targeting the Complement System to Optimize Treatment of Cold Agglutinin Disease
Target Audience
This educational activity is directed toward hematologists. Nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with cold agglutinin disease are invited to attend.
Activity Overview
This Expert Illustrations and Commentaries™ is a video-based program in which 2 experts discuss strategies for the management of cold agglutinin disease (CAD). In this activity, the faculty focus on the role of the complement system i... |
|
|
Evolving Treatments and Management Considerations for Patients with Hemophilia A
Target Audience
This educational activity is directed toward hematologists and specialty nurse practitioners and physician assistants involved in the management of patients with hemophilia A.
Activity Overview
This online activity is designed to provide a concise and focused overview on an important clinical topic and includes information on current and emerging therapies for patients with hemophilia A. The engaging, multimedia format of this program includes audio commentary from an expe... |
|
|
On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma
Program Overview
On Topic Virtual Roundtable: The Expanding Therapeutic Landscape for Targeting BCMA in Patients with Multiple Myeloma aims to provide clinical data regarding current and emerging therapeutic BCMA-directed treatment strategies via a panel of experts treating patients with multiple myeloma.
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and ot... |
|
|
Gene Therapy for Hemophilia B"The Next Step Forward in Disease Management
Target Audience
This educational activity is directed toward hematologists and hematologist-oncologists. Pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with hemophilia B are invited to attend.
Activity Overview
Gene therapy for hemophilia B has the potential to reduce the treatment burden for patients and their care partners by eliminating the need for regular prophylaxis through long-term expression of endogen... |
|
|
Real-World Perspectives in Managing CLL Treatment
Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ... |
|